Landos Biopharma Inc expected to post a loss of 91 cents a share - Earnings Preview

Landos Biopharma

19/03/2024 12:48

* Landos Biopharma Inc  LABP.OQ   LABP.O  is expected
to show no
change in quarterly revenue when it reports  results on March 21
(estimated) for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Landos Biopharma Inc is
for a
loss of 91 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Landos
Biopharma
Inc is $5.00​, below​ its last closing price of $6.64. ​​​

This summary was machine generated March 19 at 12:47 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)